1
H chemical shifts are reported in ppm relative to residual peaks of deuterated solvents. Higher-order NMR spectra were approximately interpreted as first-order spectra, where possible. The observed signal multiplicities are characterized as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, and br = broad. Coupling constants (J) were reported in Hertz (Hz).
13

C-NMR spectra [additional APT (Attached Proton Test)]: Bruker
Avance II 300 (75.5 MHz) and Bruker Avance II+ 600 (125.9 MHz).
13
C chemical shifts are reported relative to residual peaks of deuterated solvents. Low resolution ESI-MS: Finnigan LCQ. High resolution ESI-MS: Bruker APEX IV 7T FTICR MS. TLC: Merck pre-coated sheets, 0.25 mm Sil G/UV 254 . The chromatograms were viewed under UV light and/or by treatment with phosphomolybdic acid (10% in ethanol). Column chromatography: Merck silica gel, grade 60, 230-400 mesh. Solvent proportions are indicated in a volume/volume ratio. All reactions were carried out with magnetic stirring unless otherwise stated and, in the case of air-or moisture-sensitive substrates and/or reagents, were handled in flame-dried glassware under argon or nitrogen. Organic extracts were dried with anhydrous MgSO 4 . In general, chemicals and solvents were purchased from Sigma-Aldrich and Merck (Germany), or otherwise as indicated. In general, all reagents and solvents were of the highest commercially available grade and were used without further purification. Chloramine T trihydrate (CAS no. 7080-50-4) was from SigmaAldrich (product no. 31224), acetonitrile in HPLC grade for labeling was from Merck (product no. 114291). PBS (w/o Ca, Mg) was from PAN-Biotech. Used HPLC colums were "Multospher C2" (Multospher 120 RP 2, 5 µm, 250 × 3 mm, SC-Chromatographie Service, Germany), and "Chromolith" (monolithic Chromolith FastGradient RP-18 endcapped 50 × 2 mm, Merck Germany, product no. 152007). The used "C18 cartridge" was "Sep-Pak C18 Plus Light" (Waters, 130 mg sorbent, 55-105 µm particle size, product no. WAT023501). No-carrier-added (n.c.a.) sodium [I-124] iodide (A s ≤ 1203 GBq/µmol, A c > 1 MBq/µL, in 0.02 M NaOH) was obtained from Eckert & Ziegler (Berlin, Germany), and no-carrier-added sodium [I-125] iodide (Product NEZ033H010MC, A s ≥ 79.9 GBq/µmol, A c ≥ 13 MBq/µL, in 0.01 M NaOH) was purchased from PerkinElmer. Radiochemical yields (RCY) were calculated as the amount of radioactivity in the product expressed as the percent of related starting radioactivity used in the corresponding synthesis (step). The necessary decay correction was omitted in consideration of the long halflives of the nuclides used [Ref.
: http://www.srsweb.org/]. Further used abbreviations are: RCP for radiochemical purity, and EOS for end of 4 synthesis.
Indomethacyl pentaflurophenolate, compound 3a, 
Chemistry
Determination of log D values
For determining log D values using the HPLC method described within the Materials and Methods section of the corresponding article synthetic reagent mixtures were at least analyzed in triplicate. The basic cocktail was composed by adding 2 mg of triphenylene to 200 µL of toluene, followed by the addition of 20 mL methanol. For assessing the log D of a substance approximately 1 mg of it was added to 1 mL of the cocktail. Compound 7 was dissolved partly only. 5 µL of each compound solution were injected into the HPLC. A typical chromatogram with all three investigated COX-2 inhibitors plus indomethacin is shown in the following chromatogram (Supplementary Figure 1) .
Indomethacin conjugate 5 [Ind-NH-(CH 2 ) 4 -NH-3-I-Bz]
Diisopropylethylamine (0.193 mL, 0.14 g, 1.08 mmol) was added to a suspension of N-(4-aminobutyl)-2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl) acetamide hydrochloride (4) (0.25 g, 0.54 mmol) in a solution of N-hydroxysuccinimidyl 3-iodobenzoate (0.186 g, 0.54 mmol) in DMF (5 mL) and the mixture was stirred for 3 h. Thereafter, the mixture was concentrated under reduced pressure, the residue dissolved in EtOAc (80 mL) and washed with 1 M NaHSO 4 (3 × 20 mL), H 2 O (20 mL), 10% NaHCO 3 (3 × 20 mL), H 2 O (3 × 20 mL), brine (2 × 10 mL), dried, filtered and concentrated under reduced pressure. 
Indomethacin conjugate 6 (Ind-NH-(CH 2 ) 4 -NH-5-I-Nic)
WSC·HCl (0.27 g, 1.41 mmol) was added to an icecold solution of 5-iodopyridine-3-carboxylic acid (0.29 g, 1.16 mmol) and HONSu (0.16 g, 1.39 mmol) in DMF (5 mL). Thereafter, CH 2 Cl 2 was added to the reaction mixture until WSC·HCl completely dissolved. The cooling bath was removed and the mixture was stirred for an additional 1 h. After that, a freshly prepared solution of 4 (0.55 g, 1.04 mmol) and diisopropylethylamine (0.175 mL, 0.13 g, 1.11 mmol) in DMF (10 mL) was added to the solution of the active ester and the reaction mixture was stirred for a further 3 h. Thereafter, the mixture was concentrated under reduced pressure, the residue dissolved in CH 2 Cl 2 (80 mL) and washed with H 2 O (3 × 20 mL), brine (2 × 10 mL), dried, filtered and concentrated under reduced pressure. The residue was taken up in EtOAc (30 mL) and the resulting suspension was heated to reflux and cooled down to ambient temperature. The precipitate was filtered off to give 7 (0.54 g, 79%) as a colorless solid. R f = 0.19, CHCl 3 :MeOH = 20:1 (two times development). 
Mono-tert-butyl 5-iodoisophthalate (8)
pressure. The residue was taken up in a mixture of Et 2 O (50 mL) and 1 M NaHSO 4 (50 mL). The ethereal fraction was washed with H 2 O (3 × 20 mL), brine (2 × 10 mL), dried and concentrated under reduced pressure to give crude monomethyl 5-iodoisophthalate (0.9 g, 94% crude) as a colorless solid which was used for the next step without purification and characterization. R f = 0.56, EtOAc:hexane=5:7 (3% AcOH).
Boc 2 O (1.92 g, 8.80 mmol) was added to a solution of monomethyl 5-iodoisophthalate (0.9 g, 2.93 mmol) and DMAP (0.18 g, 1.47 mmol) in tBuOH (30 mL) and the reaction mixture was stirred for 16 h. Afterwards, the mixture was concentrated under reduced pressure, the residue was taken up in Et 2 O (50 mL), washed with 1 M NaHSO 4 (3 × 20 mL), H 2 O (20 mL), 10% NaHCO 3 (3 × 20 mL), H 2 O (3 × 20 mL), brine (2 × 10 mL), dried, filtered and concentrated under reduced pressure to give crude tert-butyl methyl 5-iodoisophthalate (1.05 g, 99% crude) as a yellow oil which was used for the next step without purification and characterization. R f = 0.56, EtOAc : hexane = 1:4.
1 M NaOH (3.4 mL) was added to a solution of tert-butyl methyl 5-iodoisophthalate (1.05 g, 3.1 mmol) in MeOH (10 mL) and THF (5 mL) the reaction mixture was stirred for 2 h at 50°C. Afterwards, the mixture was concentrated under reduced pressure. The residue was taken up in H 2 O (50 mL) and washed with Et 2 O (2 × 10 mL). 
tert-Butyl3-[(4-{2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetamido} butyl) carbamoyl]-5-iodobenzoate (9)
WSC·HCl (0.3 g, 1.58 mmol) was added to an icecold solution of 8 (0.5 g, 1.44 mmol) and HONSu (0.18 g, 1.58 mmol) in DMF (5 mL). Thereafter, CH 2 Cl 2 was added to the reaction mixture until WSC·HCl completely dissolved. The cooling bath was removed and the mixture was stirred for additional 16 h. The reaction mixture was concentrated under reduced pressure, the residue was
reduced pressure to give crude tert-butyl N-hydroxysuccinimidyl 5-iodoisophthalate (0.63 g, 64%) as a colorless foam which was used for the next step without purification and characterization. R f = 0.58, EtOAc:hexane = 5:7.
A solution of 4 (0.66 g, 1.42 mmol) in DMF (5 mL) followed by DIEA (0.5 mL, 0.37 g, 2.85 mmol) was added to a solution of tert-butyl N-hydroxysuccinimidyl 5-iodoisophthalate (0.63 g, 1.42 mmol) in THF (5 mL) and the reaction mixture was stirred for 2.5 h. Thereafter, the mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (70 mL), washed with 1 M NaHSO 4 (3 × 20 mL), H 2 O (20 mL), 10% NaHCO 3 (3 × 20 mL), H 2 O (3 ×20 mL), brine (2 × 10 mL), dried, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (CHCl 3 :MeOH = 20:1) to give after recrystallization from EtOAc/Et 2 O 9 (0.86 g, 80%) as a yellow solid. R f = 0.35, CHCl 3 (3% AcOH). 
3-[(4-{2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetamido}butyl) carbamoyl]-5-iodobenzoic acid (7)
TFA (2 mL) was added to a suspension of 9 (0.12 g, 0.16 mmol) in CH 2 Cl 2 /TIS/H 2 O (1 mL/0.15 mL/0.15 mL) and the reaction mixture was stirred for 15 min. The reaction mixture was concentrated under reduced pressure. The residue was triturated with Et 2 O and the resulting amorphous solid was recrystallized from MeOH/Et 2 O to give 7 (94 mg, 85%) as a yellow solid. R f = 0.23, CHCl 3 :MeOH=35:1 (3% AcOH). 
Indomethacin conjugate 10 [Ind-NH-(CH 2 ) 4 -NH-3-SnBu 3 -Bz]
Labeling precursor for 5. Bu 6 Sn 2 (0.26 mL, 0.30 g, 0.52 mmol) followed by Pd(PPh 3 )Cl 2 (10 mg, 14.3 µmol) were added to a suspension of 5 (0.28 g, 0.44 mmol) in 1,4-dioxane (5 mL) and the reaction mixture was stirred for 16 h at 85°C. The resulting black solution was cooled down to ambient temperature and concentrated under reduced pressure: The residue was thoroughly triturated with pentane (5 × 10 mL) and quickly washed with Et 2 O (2 × 5 mL). The solid residue was taken up into CH 2 Cl 2 (20 mL), the resulting suspension was filtered through Celite 
Indomethacin conjugate 11 [Ind-NH-(CH 2 ) 4 -NH-5-SnBu 3 -Nic]
Labeling precursor for 6. Bu 6 Sn 2 (0.16 mL, 0.19 g, 0.33 mmol) followed by 1,4-dioxane (3 mL) were added to a solution of 6 (0.2 g, 0.31 mmol) and Pd(PPh 3 )Cl 2 (10 mg, 14.3 µmol) in DMF (2 mL) and the reaction mixture was stirred for 16 h at 90°C. The resulting black suspension was cooled down to ambient temperature, filtered through Celite ® and the resulting solution was concentrated under reduced pressure. The residue was recrystallized from 4 H), 6.78-7.03 (m, 3 H), 6.62-6.73 (m, 1 H) , 1H), 3.79 (s, 3H), 3.65 (s, 2H) (12): Labeling precursor for 7. Bu 6 Sn 2 (0.16 mL, 0.185 g, 0.32 mmol) was added to a suspension of 9 (0.21 g, 0.28 mmol) and Pd(PPh 3 ) Cl 2 (10 mg, 14.3 µmol) in 1,4-dioxane (2 mL) and the reaction mixture was stirred at 80°C for 16 h. Afterwards, the mixture was concentrated under reduced pressure, the residue was triturated with hexane and the resulting amorphous solid was filtered off. The crude product was purified by column chromatography (EtOAc:hexane = 1:2.5; silica gel with 0.1% CaO) followed by recrystallization from Et 2 O/hexane to give 12 (0.14 g, 55%) as an amorphous colorless solid. R f = 0.37, EtOAc:hexane = 1:2.5. Preparation of [I-125] 5 was conducted in a 1.5 mL micro centrifuge tube at room temperature (24°C). 5 µL 15 mM tributylstannyl precursor 10 in methylene chloride (stored at + 4°C) were added and evaporated to dryness. The residue was re-dissolved in 20 µL acetic acid and 15 µL n.c.a. [I-125] iodide in 0.1 M NaOH aq (30-100 MBq)
Ind-NH-(CH 2 ) 4 -NH-5-[I-125]I-Iphth ([I-125]7)
Preparation of [I-125] 7 was conducted similarly to [I-125] 5. The synthesis of [I-125] 7 was conducted in a 1.5 mL sealed v-shaped GC sample vial at room temperature (24°C). First, 5 µL 15 mM tributylstannyl precursor 12 in CH2Cl2 were evaporated in a N2 stream to dryness and redissolved in 20 µL HOAc. 15 µL [I-125] iodide in 0.1 M NaOH aq were added (30-100 MBq). Labeling reaction started with addition of 25 µL 0.236 mM CAT in MeCN. After 20 min of reaction the tBu ester was cleaved by addition of 200 µL TFA and a reaction at 70°C for 12 min. The crude mixture was diluted with 100 µL water, injected into a 500 µL HPLC loop, and a HPLC separation was performed. Conditions: column: Multospher C2; flow: 1 mL/min; isocratic elution: conditions 40% EtOH aq. Effective RCY of this step was 60 ± 15%. Collected product fraction (3.0 to 4.5 min, 1.5 mL, 15 to 50 MBq [I-125] ; precursor (10 min). RCP of the product was > 95%, specific activity at EOS: 0.2 ± 0.1 GBq/µmol as determined by the hydrolyzed precursor which could not be separated properly from the product using the Multospher C2 column.
